fashion -WSS

fashion

author：explore 2025-09-06 04:41:29 - browse：48347

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： FDA clears AI tool for detecting skin cancer

focus

WSS

Results on Novartis prostate cancer therapy could expand its use

Dewpoint Therapeutics lays off staff after losing partnerships

EU regulator recommends expanding Mounjaro approval to obesity

Medicare Advantage today, explained in one chart

STAT Readout Newsletter: Biotech news today

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

focus

fashion

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

FDA clears AI tool for detecting skin cancer

Drug repurposing or repositioning? The language matters

STAT Summit: How researchers deal with rejection

Supreme Court strikes down use of affirmative action

Independent physicians launch a new lobbying group

Hepatitis C has a cure — but many Americans still lack access to it

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Alkermes shareholders re

Independent physicians launch a new lobbying group

Wikipedia

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Why doctors need education on FDA device approval process

Francis Collins on trust in science and how Covid communications failed

UnitedHealth, Optum discontinue NaviHealth name

Humana cuts profit projections as Medicare Advantage costs soar

Eli Lilly, Pfizer, and others want in on the online prescription market

focus

focus

focus

focus